New PROSPER Data Demonstrate Real-World Impact of Mogamulizumab on Symptoms and Health-Related Quality of Life in Mycosis Fungoides and Sézary Syndrome
June 29, 2026
Clinically meaningful improvements in skin symptoms reported as early as week 4 and sustained over the 48-week study period Data presented at the 6th World Congress of Cutaneous Lymphomas meeting in Montreal, Canada PRINCETON, N.J., June 29, 2026 (GLOBE NEWSWIRE) — Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa
